US3400128A - Heterocyclic intermediates - Google Patents
Heterocyclic intermediates Download PDFInfo
- Publication number
- US3400128A US3400128A US326338A US32633863A US3400128A US 3400128 A US3400128 A US 3400128A US 326338 A US326338 A US 326338A US 32633863 A US32633863 A US 32633863A US 3400128 A US3400128 A US 3400128A
- Authority
- US
- United States
- Prior art keywords
- benzene
- thienyl
- ether
- ketone
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000000623 heterocyclic group Chemical group 0.000 title description 3
- 239000000543 intermediate Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 28
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 78
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- -1 mineral acids Chemical class 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 9
- 150000002576 ketones Chemical class 0.000 description 9
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 125000002541 furyl group Chemical group 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960002449 glycine Drugs 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- GUTQMBQKTSGBPQ-UHFFFAOYSA-N dithiophen-2-ylmethanone Chemical compound C=1C=CSC=1C(=O)C1=CC=CS1 GUTQMBQKTSGBPQ-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- PYOYAYUOWCTPNL-UHFFFAOYSA-N (2-amino-5-chlorophenyl)-thiophen-2-ylmethanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C1=CC=CS1 PYOYAYUOWCTPNL-UHFFFAOYSA-N 0.000 description 2
- UDLAUVFRZXIQJS-UHFFFAOYSA-N 1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1C(=O)CN=CC2=CC=CC=C21 UDLAUVFRZXIQJS-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 2
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- KCTBOHUTRYYLJA-UHFFFAOYSA-N lithium;2h-furan-2-ide Chemical compound [Li+].C=1C=[C-]OC=1 KCTBOHUTRYYLJA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- GUAGHTDLIMFQDF-UHFFFAOYSA-N (2-amino-5-chlorophenyl)-(1h-pyrrol-2-yl)methanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C1=CC=CN1 GUAGHTDLIMFQDF-UHFFFAOYSA-N 0.000 description 1
- LRZCHOZJGIXTRX-UHFFFAOYSA-N (2-aminophenyl)-thiophen-2-ylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CS1 LRZCHOZJGIXTRX-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- FUTAICVDCZLQCL-UHFFFAOYSA-N 2-(chloromethyl)-3-oxido-4-phenylquinazolin-3-ium Chemical compound [O-][N+]1=C(CCl)N=C2C=CC=CC2=C1C1=CC=CC=C1 FUTAICVDCZLQCL-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KVBZGDNWBRCXHF-UHFFFAOYSA-N 3-oxidoquinazolin-3-ium Chemical compound C1=CC=CC2=C[N+]([O-])=CN=C21 KVBZGDNWBRCXHF-UHFFFAOYSA-N 0.000 description 1
- QQUIWIVTEWQHKA-UHFFFAOYSA-N 3h-1,4-benzodiazepine Chemical group C1=NCC=NC2=CC=CC=C21 QQUIWIVTEWQHKA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OEGHKMSYOJOVNJ-UHFFFAOYSA-N 4-oxido-3H-1,4-benzodiazepin-4-ium Chemical compound N1=CC[N+](=CC2=C1C=CC=C2)[O-] OEGHKMSYOJOVNJ-UHFFFAOYSA-N 0.000 description 1
- UXMVQZIDRMBYRK-UHFFFAOYSA-N 6-chloro-2-methyl-3,1-benzoxazin-4-one Chemical compound C1=C(Cl)C=C2C(=O)OC(C)=NC2=C1 UXMVQZIDRMBYRK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MIHFTSQNVCCOLD-UHFFFAOYSA-N Cl.C=1C=CSC=1C(=O)C1=CC=CS1 Chemical compound Cl.C=1C=CSC=1C(=O)C1=CC=CS1 MIHFTSQNVCCOLD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001249542 Leonia <angiosperm> Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- HRQVBZRPLVKCIQ-UHFFFAOYSA-M [Br-].[Mg+]C1=CC=CN1 Chemical compound [Br-].[Mg+]C1=CC=CN1 HRQVBZRPLVKCIQ-UHFFFAOYSA-M 0.000 description 1
- QOTAEASRCGCJDN-UHFFFAOYSA-N [C].CO Chemical compound [C].CO QOTAEASRCGCJDN-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- DKEKURXRUXRNES-UHFFFAOYSA-N bis(1h-pyrrol-2-yl)methanone Chemical compound C=1C=CNC=1C(=O)C1=CC=CN1 DKEKURXRUXRNES-UHFFFAOYSA-N 0.000 description 1
- HMKCSFHWMJHMTG-UHFFFAOYSA-N bis(furan-2-yl)methanone Chemical compound C=1C=COC=1C(=O)C1=CC=CO1 HMKCSFHWMJHMTG-UHFFFAOYSA-N 0.000 description 1
- FBVHMRJBOONEGW-UHFFFAOYSA-N bis[3-(2-amino-5-chlorophenyl)furan-2-yl]methanone Chemical compound NC1=C(C=C(C=C1)Cl)C1=C(OC=C1)C(=O)C=1OC=CC1C1=C(C=CC(=C1)Cl)N FBVHMRJBOONEGW-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- SNHOZPMHMQQMNI-UHFFFAOYSA-N lithium;2h-thiophen-2-ide Chemical compound [Li+].C=1C=[C-]SC=1 SNHOZPMHMQQMNI-UHFFFAOYSA-N 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- HDGAHFKUNNTTDW-UHFFFAOYSA-L magnesium;thiophene;dibromide Chemical compound [Mg+2].[Br-].[Br-].C=1C=CSC=1 HDGAHFKUNNTTDW-UHFFFAOYSA-L 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- OIEFZHJNURGFFI-UHFFFAOYSA-N n-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(NC(C)=O)=C1 OIEFZHJNURGFFI-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Definitions
- R4 R4 0 R and R are selected from the group consisting of hydrogen and lower alkyl
- R is selected from the group consisting of hydrogen, halogen, nitro and lower alkoxy
- R is selected from the group consisting of pyrryl, furyl and thienyl.
- benzodiazepine compounds of the invention conform to any of the four following formulas included within the scope of Formula I above.
- the compounds of Formula II are S-R -3H-l,4-benzodiazepin-2(1H)-ones, those of Formula III are 5-R -3H- 1,4-benzodiazepin-2(lH)-one 4-oxides, those Olf Formula IV are 2-amino5-R -3H-1,4-benzodiazepines, and those of Formula V are 2-amino-5-R -3H-1,4-benzodiazepine 4- oxides.
- lower alkyl comprehends both straight and branched chain lower alkyl groups such as methyl, ethyl, propyl, isopropyl, and the like.
- halogen includes all four halogens, i.e. bromine, iodine, fluorine and chlorine.
- Compounds conforming to Formulas IIV, i.e. Formula 1, above are especially preferred where R is chlorine.
- the heterocyclic moiety (R in the compounds of the invention is selected from the group consisting of pyrryl, furyl and thienyl.
- the invention comprehends a five-membered monoheterocyclic ring of the formula wherein Y is either NH, 0 or S; joined to the 5- position atom of a 3H-1,4-benzodiazepine moiety by a carbon to carbon bond.
- the compounds of Formulas II-V above form acid addition salts with medicinally acceptable acids.
- the compounds form medicinally acceptable acid addition salts with both inorganic and organic acids such as mineral acids, e.g. hydrohalic acids, for example hydrochloric acid, hydrobromic acid, and the like, nitric acid, sulfuric acid, phosphoric acid, acetic acid, formic acid, fumaric acid, succinic acid, meleic acid, p-toluene SlJilfOl'liC acid, methyl sulfonic acid, and the like.
- mineral acids e.g. hydrohalic acids, for example hydrochloric acid, hydrobromic acid, and the like, nitric acid, sulfuric acid, phosphoric acid, acetic acid, formic acid, fumaric acid, succinic acid, meleic acid, p-toluene SlJilfOl'liC acid, methyl sulfonic acid, and the like.
- Certain of these ketones are novel and can be prepared by reacting a 2-methy1-3,1-benzoxazin-4-one of the following formula (VIII) N-CCH3 R2 I wherein R has the same meaning as above with a heterocyclic Grignard reagent wherein the heterocyclic moiety conforms to R such as a heterocyclic magnesium halide compound.
- a heterocyclic lithium compound can be used.
- the compounds conforming to Formula I above can be made from the compounds conforming to Formula VII by a variety of alternative routes.
- the reaction is preferably effected in a solvent such as pyridine, dimethyl formamide, or the like. It is also preferable to have an anion of a strong acid present in the reaction mixture and there-fore it is convenient to use reagents in the form of a salt of a strong organic or inorganic acid, e.g. glycine hydrochloride, glycine ethyl ester hydrochloride, or part of the pyridine as pyridine hydrochloride.
- a solvent such as pyridine, dimethyl formamide, or the like.
- reagents in the form of a salt of a strong organic or inorganic acid, e.g. glycine hydrochloride, glycine ethyl ester hydrochloride, or part of the pyridine as pyridine hydrochloride.
- 3H-l,4-benzodiazepin-2(lH)-one compounds corresponding to Formula II above can also be produced by reacting a ketone corresponding to Formula VII above with a haloacetyl halide, such as chloroacetyl chloride, bromoacetyl bromide and the like to produce a 2-haloacetan1inophenyl R ketone corresponding to the formula (IX) R1 wherein R R and R have the same meaning as above and X is a halogen.
- a haloacetyl halide such as chloroacetyl chloride, bromoacetyl bromide and the like
- the compounds corresponding to Formula IX can then be directly cyclized by reaction with ammonia to yield compounds corresponding to Formula II above.
- the compounds of Formula IX can also be reacted with ammonia so that the halogen atom is replaced by the amino group yielding a 2-aminoacetaminophenyl R ketone which can then be cyclized to a compound corresponding to Formula II above.
- 2-aminophenyl R ketones corresponding to Formula VII above wherein R is hydrogen can be treated with hydroxylamine hydrochloride to form corresponding 2- aminophenyl R ketoximes.
- the reaction of the oxime with chloroacetyl chloride produces a chloracetamino derivative which cyclizes to form a 2-chloromethyl-4-phenylquinazoline 3-oxide corresponding to the following forwherein R and R have the same meaning as above.
- the quinazoline of Formula X above can then be reacted With an alkali metal hydroxide or alkaline earth metal hydroxide, preferably in an inert organic solvent such as ethanol, dioxane, or the like, to enlarge the ring to produce a 5-R -3H-1,4-benzodiazepin-2(lH)-one 4- oxide conforming to Formula III above, wherein R is hydrogen, or it can be reacted with ammonia or a lower alkylamine to yield a Z-amino 5-R -3H-1,4-.benzodiazepin 4-oxide or a 2-lower alkylamino-5-R -3H-1,4-benzodiazepin 4-oxide respectively.
- the latter two products are represented by Formula V above.
- the compounds of Formula III can be converted to compounds of Formula H by treatment with phosphorus trichloride or by catalytic hydrogenation, for example in the presence of Raney nickel.
- compounds of Formula V can be converted into compounds represented by Formula IV above.
- the benzodiazepine compounds corresponding to Formula I above are valuable therapeutic agents. They are useful as sedatives and anticonvulsants and can be used as tranquilizers or muscle relaxants.
- the compounds can be taken internally with dosage adjusted to individual requirements. Thus they can be administered parenterally or orally in conventional pharmaceutical dosage forms as solid or liquid dosage forms such as tablets, capsules, suspensions, elixirs and the like. As set forth above the compounds can also be administered in the form of their medicinally acceptable acid addition salts.
- Example 1 A solution of 52.0 g. of 2-methyl-6-chloro-4I-I-3,l-benzoxazin-4-one in 250 cc. of dry benzene was prepared in a 3-necked flask with slight warming. The solution was then cooled and cc. of dry ether was added. In another 3-necked round bottom flasischenr anhydrous conditionsa solution of furyl lithium was prepared as follows: 5.0 g. of cut lithium wire was reacted with 52.5 g. of bromobenzene in 150 cc. of ether under reflux conditions (2 hours) to form phenyl lithium. The solution was then cooled to room temperature and 17.0 g. of freshly distilled furan in 100 cc.
- the reaction mixture was cooled and treated with -cc. of 6 N hydrochloric acid and ice, and the resultant mixture concentrated to dryness.
- the residue was dissolved in 230 cc. of ethyl. alcohol containing 35 cc. of concentrated hydrochloric acid and refluxed for 4 hours.
- the solution was then concentrated to dryness, suspended in water, and made basic with excess potassium carbonate.
- the basic material that separated was dissolved in benzene.
- the benzene solution was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness.
- the residual oil was boiled out with one liter of heptane (B.P. -100”) and the heptane soluble separated and recovered by concentration.
- the residual oil crystallized on tritura tion with methanol and was recrystallized from methanol to give 2-amino-5-chlorophenyl-2-furyl ketone melting at 113-114.
- Example 2 1 ml. (11 mmoles) of bromoacetyl bromide was added to a solution of 4.4 -g. of 2-amino-5-chloropher1yl-2-furyl ketone dissolved in 800 ml. of ether. The reaction mixture was swirled and after 7 minutes the turbid ether solution was washed with 300 ml. of water. The addition of the bromoacetyl bromide was repeated 4 times. Following the final addition of acid halide, the reaction mixture was washed several times with water until the ether solution was neutral. The ether solution was then dried over sodium sulfate. The desiccant was removed by filtration and the filtrate was concentrated on a water bath.
- Example 3 200 ml. of 20% ammonia in methanol was added to a solution of 2.1 g. of 2-bromoacetylamino-S-chlorophenyl Z-furyl ketone in 200 ml. of methanol. The solution was swirled. After remaining overnight at room temperature, the reaction mixture was concentrated at reduced pressure on a water bath. The temperature of the water bath did not exceed 60". The residue was leached with boiling C.P. ether. Dry hydrogen chloride gas was bubbled into the ether solution.
- Example 4 A Grignard reagent was prepared by the addition of 7.8 g. of ethyl iodide to 1.2 g. of magnesium in 200 ml.
- the completed Grignard reaction was held at 30 for 1 hour and decomposed with ammonium chloride in ice water.
- the aqueous layer was separated from the ether layer, and the aqueous layer then extracted with ether.
- the combined ether extracts were concentrated to a solid and the solid treated with 100 ml. of methanol, 40 ml. of 30% sodium hydroxide and 60 ml. of water at reflux for 1 hour.
- the product was crystallized from a petroleum solvent boiling at 60-68 (Skellysolve B), yielding 2-amino-5-chlorophenyl 2-pyrryl ketone melting at 148-149.
- Example 5 4.4 g. of Z-amino-S-chlorophenyl 2-pyrryl ketone was dissolved in 350 ml. of anhydrous ether with an eflicient stirrer so that good contact is obtained. To this in five alternate and equal portions are added a total quantity of 6.05 g. of bromoacetyl bromide in 125 ml. of dry ether, and 30 ml. of 1 N sodium hydroxide.
- Example 6 30 g. of 2-bromoacetamido-5-ch1orophenyl 2-pyrryl ketone was dissolved in 250 ml. of ether. This solution was slowly added to 250 g. of liquid ammonia with stirring. On standing overnight, the excess ammonia and all the ether evaporated to yield a white powder. This residual white powder was washed with water and recrystallized from ethanol yielding 2-aminoacetamino-5-chlorophenyl 2-pyrryl ketone melting at 196197.
- Example 7 10.5 g. of Z-aminoacetamino-5-chlorophenyl 2-pyrryl ketone was dissolved in 300 ml. of pyridine. After refluxing for /2 hour, 50 ml. of pyridine was removed by distillation and then replaced by fresh, dry pyridine. After refluxing for 2 /2 hours, 100 ml. of pyridine was removed and replaced by fresh pyridine. Refluxing was then continued for 5 hours and the solution concentrated to a solid under vacuum. The residue was crystallized from ethanol twice to yield 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2( 1H)-one melting at 262-263 6
- Example 8 37 g.
- Example 10 A solution of 1.5 g. of 2-amino-4-methoxyphenyl 2- thienyl ketone and 1.3 g. of glycine ethyl ester hydrochloride in 25 cc. of pyridine was refluxed for 1 hour. After distilling off 5 cc. of pyridine, an additional 1.3 g. of glycine ethyl ester hydrochloride was added and the reaction mixture stirred and refluxed for 16 hours. After concentration to dryness in vacuo, the residue was partitioned between benzene and water.
- the benzene layer was concentrated to dryness in vacuo and the residue was crystallized from benzene-hexane to give S-methoxy- 5-(2-thienyl)-3H-1,4-benzodiazepin 2(1H) one which after decolorization in acetone was recrystallized frombenzene-hexane and melted at 2125-214". Additional product was obtained by making the aqueous layer alkaline.
- Example 11 Thiophene magnesium bromide prepared by the reaction of 17.8 g. of 2-bromo-thiophene with 2.6 g. of magnesium in 200 cc. of ether was slowly added to 16.1 g. of 2-methyl-3,1-4H-benzoxazine-4-one dissolved in 300 cc. of benzene and 100 cc. of ether while keeping the temperature at 5. A yellow precipitate formed.
- the reaction mixture was kept at 0-5 for hr. and then for 1 hr. at room temperature. It was then chilled in a salt-ice bath and decomposed by the addition of 200 cc. of cold 2 N hydrochloric acid.
- Example 12 A solution of 11.0 g. of Z-acetaminophenyl 2-thienyl ketone in 200 cc. of ethanol and cc. of 6 N hydrochloric acid was refluxed for 2 /2 hrs. On cooling 8.0 g. of Z-aminophenyl 2-thienyl ketone hydrochloride crystallized. The free base was liberated (6.8 g.) but was not crystallized. An additional 2.2 g. of Z-aminophenyl Z-thienyl ketone was isolated from the alcoholic mother liquors. A solution of 9.0 g. of Z-aminophenyl 2-thienyl ketone and 9.3 g.
- Example 13 A solution of 3.0 g. of 2-aminophenyl 2-thienyl ketone in 150 cc. of ether was stirred with 50 cc. of 0.5 N sodium hydroxide at 5, and 3.1 g. of bromoacetyl bromide was then slowly added. After 30 minutes in the ice bath, the organic layer was separated, diluted with benzene, washed with water, and dried over sodium sulfate. After distillation of solvent in vacuo, the residue of crude 2-bromoacetamino 2-thienyl ketone was dissolved in 100 cc. of 20% ammonia in methanol (w./v.) and kept overnight at room temperature.
- Example A Grignard reagent prepared by the reaction of 26.1 g. of 2-bromothiophene and 3.9 g. of magnesium in 200 cc. of ether was slowly added to a suspension of 29.3 g. of 6-chloro-2-methyl-3,1-4H-benzoxazin-4-one in 450 cc. of benzene and 150 cc. of ether while maintaining the temperature at 05. A yellow precipitate formed.
- the reaction mixture was stirred for 4 hr. in an ice bath and for hr. at room temperature, then chilled in a salt-ice bath, and decomposed by the addition of 250 cc. of cold 2 N hydrochloric acid.
- Example 16 Crude Z-acetamino-S-chlorophenyl 2-thienyl ketone prepared as described above in Example 15 in a 0.05 mol run was hydrolyzed by refluxing for 2 hrs. with cc. of ethanol and 50 cc. of concentrated hydrochloric acid. After evaporation of the reaction mixture to dryness in vacuo the residue was stirred with water and the resulting yellow crystalline product filtered off. Crystallization from hexane yielded 2-amino-5-chlorophenyl 2- thienyl ketone which upon further crystallization from hexane melted at 94.5-96".
- Example 17 20.8 g. of 2-acetamino-5-chlorophenyl 2-thienyl ketone was hydrolyzed by refluxing in 400 cc. of ethanol and 200 cc. of 6 N hydrochloric acid for 3 hrs. The solvent was distilled off in vacuo and the residue stirred with 200 cc. of ether and 200 cc. of water. The reaction mixture was made slightly alkaline with 40% sodium hydroxide, cooled to 05, and 15.0 g. of bromoacetyl bromide slowly added with the simultaneous addition of 1 N sodium hydroxide to keep the reaction alkaline.
- Example 18 A solution of 4 g. of 2-amino-5-chlorophenyl 2-thienyl ketone and 3.5 g. of glycine ethyl ester hydrochloride in 75 cc. of pyridine was heated to reflux for 1 hr. After distilling off 10 cc. of pyridine, an additional 3.5 g. of glycine ethyl ester hydrochloride was added and the reaction refiuxed for a total of 17 hrs. Solvent was evaporated in vacuo and the residue was partitioned between benzene and water.
- Example 19 14.9 g. of 2-bromoacetamino-5-chlorophenyl Z-thienyl ketone was stirred for 17 hrs. with 500cc. of 20% (w./v.) ammonia in methanol for 17 hrs. A small amount of insoluble material was filtered off and the filtrate concentrated to dryness in vacuo. The residue was partitioned between benzene and water and the organic layer separated, dried over sodium sulfate and concentrated to dryness in vacuo. The residual 5.2 g. which did not crystallize was redissolved in benzene and extracted with dilute hydrochloric acid. Only 600 mg. of yellow material remained in the benzene layer.
- the acid layer was made slightly alkaline with dilute sodium hydroxide and reextracted with benzene.
- Example 21 1.2 cc. of chloroacetyl chloride was added to a solution of 1.95 g. of the 2-amino-5-chlorophenyl 2-thienyl ketoxime obtained above in Example 20 in 10 cc. of acetic acid. There was a slight heat of reaction and the mixture was then kept at Gil-70 for 2 hrs. Solvent was then distilled off in vacuo, and the residue dissolved twice in benzene and concentrated to dryness in vacuo.
- Example 22 A suspension of 850 mg. of 6-chloro-2-chloromethyl-4- (2-thienyl)quinazoline 3-oxide in 20 cc. of 40% methylamine in methanol was stirred for 30 minutes in an ice bath and then stirred for 2 hrs. at room temperature. After chilling overnight in the refrigerator, 7-chloro-2- methylamino 5 (2 thienyl) 3H 1,4 benzodiazepine 4-oxide was filtered off and after crystallization from ethanol melted at 274-27 6.
- Example 23 A suspension of 1.0 g. of 6-chloro-2-chloromethyl-4 (2-thienyl)quinazoline 3-oxide in a mixture of 25 cc. of ethanol, 3.2 cc, of 1 N sodium hydroxide, and 5 cc. of acetone was stirred at 35 for /2 hr. and then for 16 hrs.
- Example 24 To a solution of 1.12 g. of sodium methoxide in 100 cc. of methanol, 5.0 g. of 5-(2-thienyl)-3H-1,4-benzodiazepin-2-(1H)-one was added. After stirring for 30 minutes, the mixture was concentrated to dryness in vacuo. The residue was dissolved in 50 cc. of dimethylformamide and concentrated to a small volume in vacuo to remove traces of methanol. The residue was again diswherein R is selected from the group consisting of hydrogen, halogen, nitro and lower alkoxy; and R is selected from the group consisting of pyrryl and furyl.
- R is selected from the group consisting of hydrogen, halogen, nitro and lower alkoxy, and R is selected from the group consisting of pyrryl and furyl.
Description
United States Patent 3,400,128 HETEROCYCLIC INTERMEDIATES Leo Berger, Montclair, Arthur Stempel, Teaneck, Leo Henryk Sternbach, Upper Montclair, and Edward Wenis, Leonia, N.J., assignors to Hotfmann-La Roche Inc., Nutley, N.J., a corporation of New Jersey N 0 Drawing. Original application June 20, 1961, Ser. No. 118,243. Divided and this application Nov. 27, 1963, Ser. No. 326,338
4 Claims. (Cl. 260256.4)
CHz
and their acid addition salts; wherein A is selected from the group consisting of (I) NH-Ra N- and N=CH B is selected from the group consisting of -C=N and -C=N l J R4 R4 0 R and R are selected from the group consisting of hydrogen and lower alkyl; R is selected from the group consisting of hydrogen, halogen, nitro and lower alkoxy; and R is selected from the group consisting of pyrryl, furyl and thienyl.
Thus the benzodiazepine compounds of the invention conform to any of the four following formulas included within the scope of Formula I above.
(III) 3,400,128 Patented Sept. 3, 1968 R4 0 wherein R R R and R have the same meaning as above.
The compounds of Formula II are S-R -3H-l,4-benzodiazepin-2(1H)-ones, those of Formula III are 5-R -3H- 1,4-benzodiazepin-2(lH)-one 4-oxides, those Olf Formula IV are 2-amino5-R -3H-1,4-benzodiazepines, and those of Formula V are 2-amino-5-R -3H-1,4-benzodiazepine 4- oxides.
The term lower alkyl comprehends both straight and branched chain lower alkyl groups such as methyl, ethyl, propyl, isopropyl, and the like. The term halogen includes all four halogens, i.e. bromine, iodine, fluorine and chlorine. Compounds conforming to Formulas IIV, i.e. Formula 1, above are especially preferred where R is chlorine. As set forth above the heterocyclic moiety (R in the compounds of the invention is selected from the group consisting of pyrryl, furyl and thienyl. Thus, the invention comprehends a five-membered monoheterocyclic ring of the formula wherein Y is either NH, 0 or S; joined to the 5- position atom of a 3H-1,4-benzodiazepine moiety by a carbon to carbon bond.
As stated above the compounds of Formulas II-V above form acid addition salts with medicinally acceptable acids. Thus the compounds form medicinally acceptable acid addition salts with both inorganic and organic acids such as mineral acids, e.g. hydrohalic acids, for example hydrochloric acid, hydrobromic acid, and the like, nitric acid, sulfuric acid, phosphoric acid, acetic acid, formic acid, fumaric acid, succinic acid, meleic acid, p-toluene SlJilfOl'liC acid, methyl sulfonic acid, and the like.
The compounds of Formulas IIV above are prepared from ketones conforming to the following formula (VII) wherein R R and R have the same meaning as above. Certain of these ketones are novel and can be prepared by reacting a 2-methy1-3,1-benzoxazin-4-one of the following formula (VIII) N-CCH3 R2 I wherein R has the same meaning as above with a heterocyclic Grignard reagent wherein the heterocyclic moiety conforms to R such as a heterocyclic magnesium halide compound. Alternatively a heterocyclic lithium compound can be used. Examples of such are furyl lithium, pyrryl lithium, thienyl lithium, Z-thienyl magnesium bromide, 2- pyrryl magnesium bromide, 2-f-uryl magnesium bromide, and the like. The reaction produces a ketone conforming to Formula VII above.
The compounds conforming to Formula I above can be made from the compounds conforming to Formula VII by a variety of alternative routes. Of the compounds conforming to Formula I, those conforming to Formula II, i.e. 3H-l,4-benzodiazepin-2(lH)-ones can be prepared by several different methods of synthesis. They can be directly synthesized by the reaction of a Z-aminophenyl R ketone (wheren R =pyrryl, furyl, thenyl) of Formula VII above with glycine or an ester thereof. According to this method the ketone is heated with glycine or a glycine ester; for example a glycine lower alkyl ester such as glycine ethyl ester. The reaction is preferably effected in a solvent such as pyridine, dimethyl formamide, or the like. It is also preferable to have an anion of a strong acid present in the reaction mixture and there-fore it is convenient to use reagents in the form of a salt of a strong organic or inorganic acid, e.g. glycine hydrochloride, glycine ethyl ester hydrochloride, or part of the pyridine as pyridine hydrochloride.
3H-l,4-benzodiazepin-2(lH)-one compounds corresponding to Formula II above can also be produced by reacting a ketone corresponding to Formula VII above with a haloacetyl halide, such as chloroacetyl chloride, bromoacetyl bromide and the like to produce a 2-haloacetan1inophenyl R ketone corresponding to the formula (IX) R1 wherein R R and R have the same meaning as above and X is a halogen.
The compounds corresponding to Formula IX can then be directly cyclized by reaction with ammonia to yield compounds corresponding to Formula II above. The compounds of Formula IX can also be reacted with ammonia so that the halogen atom is replaced by the amino group yielding a 2-aminoacetaminophenyl R ketone which can then be cyclized to a compound corresponding to Formula II above.
2-aminophenyl R ketones corresponding to Formula VII above wherein R is hydrogen can be treated with hydroxylamine hydrochloride to form corresponding 2- aminophenyl R ketoximes. The reaction of the oxime with chloroacetyl chloride produces a chloracetamino derivative which cyclizes to form a 2-chloromethyl-4-phenylquinazoline 3-oxide corresponding to the following forwherein R and R have the same meaning as above.
The quinazoline of Formula X above can then be reacted With an alkali metal hydroxide or alkaline earth metal hydroxide, preferably in an inert organic solvent such as ethanol, dioxane, or the like, to enlarge the ring to produce a 5-R -3H-1,4-benzodiazepin-2(lH)-one 4- oxide conforming to Formula III above, wherein R is hydrogen, or it can be reacted with ammonia or a lower alkylamine to yield a Z-amino 5-R -3H-1,4-.benzodiazepin 4-oxide or a 2-lower alkylamino-5-R -3H-1,4-benzodiazepin 4-oxide respectively. The latter two products are represented by Formula V above. The compounds of Formula III can be converted to compounds of Formula H by treatment with phosphorus trichloride or by catalytic hydrogenation, for example in the presence of Raney nickel. By the same procedures compounds of Formula V can be converted into compounds represented by Formula IV above.
Compounds corresponding to Formulas II and III above wherein R represents hydrogen can be converted to corresponding compounds wherein R represents lower alkyl by alkylation. This alkylation can be effected with a di azoalkane, alkyl sulfate or alkyl halide in a medium such as ether, benzene, alcohol, dimethylformamide or dioxane in the presence of an alkali metal or a derivative thereof in the form of an alcoholate, hydride or amide, e.g. sodium methoxide, lithium hydride, sodium amide, or the like. Alternatively compounds corresponding to Formulas II and III wherein R is lower alkyl can be directly produced by using compounds corresponding to Formula VII above wherein R is lower alkyl. as starting materials. These can be produced by alkylation of compounds corresponding to Formula VII wherein R is hydrogen.
The benzodiazepine compounds corresponding to Formula I above, i.e. those of Formulas II-V inclusive, are valuable therapeutic agents. They are useful as sedatives and anticonvulsants and can be used as tranquilizers or muscle relaxants. The compounds can be taken internally with dosage adjusted to individual requirements. Thus they can be administered parenterally or orally in conventional pharmaceutical dosage forms as solid or liquid dosage forms such as tablets, capsules, suspensions, elixirs and the like. As set forth above the compounds can also be administered in the form of their medicinally acceptable acid addition salts.
The following examples are illustrative of the invention but not limitative thereof. All temperatures are in degrees centigrade.
Example 1 A solution of 52.0 g. of 2-methyl-6-chloro-4I-I-3,l-benzoxazin-4-one in 250 cc. of dry benzene was prepared in a 3-necked flask with slight warming. The solution was then cooled and cc. of dry ether was added. In another 3-necked round bottom flaskunder anhydrous conditionsa solution of furyl lithium was prepared as follows: 5.0 g. of cut lithium wire was reacted with 52.5 g. of bromobenzene in 150 cc. of ether under reflux conditions (2 hours) to form phenyl lithium. The solution was then cooled to room temperature and 17.0 g. of freshly distilled furan in 100 cc. of dry ether was added and the mixture refluxed for 3 hours. The solution containing the fury] lithium was then added to the solution of the benzoxazine under anhydrous conditions at room temperature and the mixture refluxed for 1.5 'hours to complete the reaction.
The reaction mixture was cooled and treated with -cc. of 6 N hydrochloric acid and ice, and the resultant mixture concentrated to dryness. The residue was dissolved in 230 cc. of ethyl. alcohol containing 35 cc. of concentrated hydrochloric acid and refluxed for 4 hours. The solution was then concentrated to dryness, suspended in water, and made basic with excess potassium carbonate. The basic material that separated was dissolved in benzene. The benzene solution was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residual oil was boiled out with one liter of heptane (B.P. -100") and the heptane soluble separated and recovered by concentration. The residual oil crystallized on tritura tion with methanol and was recrystallized from methanol to give 2-amino-5-chlorophenyl-2-furyl ketone melting at 113-114.
Example 2 1 ml. (11 mmoles) of bromoacetyl bromide was added to a solution of 4.4 -g. of 2-amino-5-chloropher1yl-2-furyl ketone dissolved in 800 ml. of ether. The reaction mixture was swirled and after 7 minutes the turbid ether solution was washed with 300 ml. of water. The addition of the bromoacetyl bromide was repeated 4 times. Following the final addition of acid halide, the reaction mixture was washed several times with water until the ether solution was neutral. The ether solution was then dried over sodium sulfate. The desiccant was removed by filtration and the filtrate was concentrated on a water bath. The residue was first triturated with a petroleum solvent boiling at 60-68 (Skellysolve B) and then recrystallized from 1 liter of said petroleum solvent to yield 2-bromoacetamino- 5-chl;)rophenyl 2-furyl ketone melting at 87-88 (uncorr.
Example 3 200 ml. of 20% ammonia in methanol was added to a solution of 2.1 g. of 2-bromoacetylamino-S-chlorophenyl Z-furyl ketone in 200 ml. of methanol. The solution was swirled. After remaining overnight at room temperature, the reaction mixture was concentrated at reduced pressure on a water bath. The temperature of the water bath did not exceed 60". The residue was leached with boiling C.P. ether. Dry hydrogen chloride gas was bubbled into the ether solution. The crude product, 7-chloro-5-(2- furyl)-3H-l,4-benzodiazepin-2( 1H) one hydrochloride, was collected on a Buchner funnel, dissolved in water, and the resulting solution saturated with potassium carbonate. The solid base, 7-chloro-5-(2-furyl)-3H-1,4-benzodiazepin-2(1H)-one, was isolated by filtration, air dried for several hours, and then crystallized from acetone; M.P. 245-246 (uncorr.)
Example 4 A Grignard reagent was prepared by the addition of 7.8 g. of ethyl iodide to 1.2 g. of magnesium in 200 ml.
of dry ether containing 2 mg. of iodine. To this reaction solution 3.4 g. of dry distilled pyrrole in 25 ml. of dry ether was added.
The above pyrrole Grignard solution was added to g. of 6-chloro-2-methyl-4H-3,1-benzoxazin-4-one and 100 ml. of dry ether.
The completed Grignard reaction was held at 30 for 1 hour and decomposed with ammonium chloride in ice water. The aqueous layer was separated from the ether layer, and the aqueous layer then extracted with ether. The combined ether extracts were concentrated to a solid and the solid treated with 100 ml. of methanol, 40 ml. of 30% sodium hydroxide and 60 ml. of water at reflux for 1 hour. The product was crystallized from a petroleum solvent boiling at 60-68 (Skellysolve B), yielding 2-amino-5-chlorophenyl 2-pyrryl ketone melting at 148-149.
Example 5 4.4 g. of Z-amino-S-chlorophenyl 2-pyrryl ketone was dissolved in 350 ml. of anhydrous ether with an eflicient stirrer so that good contact is obtained. To this in five alternate and equal portions are added a total quantity of 6.05 g. of bromoacetyl bromide in 125 ml. of dry ether, and 30 ml. of 1 N sodium hydroxide. The ether layer was separated and the aqueous solution was extracted with ether five minutes after the final addition of the reactants, and the ether extract concentrated to a solid which was crystallized from methanol (carbon) yielding Z-bromoacetamino-S-chlorophenyl 2-pyrryl ketone as a colorless material melting at 149150.
Example 6 30 g. of 2-bromoacetamido-5-ch1orophenyl 2-pyrryl ketone was dissolved in 250 ml. of ether. This solution was slowly added to 250 g. of liquid ammonia with stirring. On standing overnight, the excess ammonia and all the ether evaporated to yield a white powder. This residual white powder was washed with water and recrystallized from ethanol yielding 2-aminoacetamino-5-chlorophenyl 2-pyrryl ketone melting at 196197.
Example 7 10.5 g. of Z-aminoacetamino-5-chlorophenyl 2-pyrryl ketone was dissolved in 300 ml. of pyridine. After refluxing for /2 hour, 50 ml. of pyridine was removed by distillation and then replaced by fresh, dry pyridine. After refluxing for 2 /2 hours, 100 ml. of pyridine was removed and replaced by fresh pyridine. Refluxing was then continued for 5 hours and the solution concentrated to a solid under vacuum. The residue was crystallized from ethanol twice to yield 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2( 1H)-one melting at 262-263 6 Example 8 37 g. of anhydrous aluminum chloride was added slowly in portions to a suspension of 27.4 g. of 2-thenoylchloride and 31.0 g. of m-acetanisidine in 150 cc. of carbon disulfide kept at 2025. The suspension was stirred for hr. after the addition was completed, then kept at room temperature overnight. A dark viscous mass had separated in the flask. The reaction mixture was then stirred and heated to reflux for 1 hr. After cooling, carbon disulfide was decanted oif and the residue decomposed with ice and dilute hydrochloric acid. The oil that separated was extracted with benzene and the organic layer then washed with dilute hydrochloric acid, water, dilute sodium hydroxide, and water. After drying over sodium sulfate, solvent was removed by concentration in vacuo. The residue was dissolved in 500 cc. of benzene and a 100 cc. aliquot removed for chromatography. The 100 cc. of aliquot in benzene was passed through a column containing 150 g. of Woelm alumina, grade I. The first fractions, eluted with benzene, were crystallized from hexane and yielded Z-acetamino-4-methoxyphenyl 2- thienyl ketone which upon recrystallization from hexane melted at 93-935 Example 9 A solution of 2.7 g. of Z-acetamino-4-methoxyphenyl 2-thienyl ketone in 30 cc. of acetic acid and 30 cc. of hy drochloric acid was refluxed for 3 hours. The reaction mixture was concentrated to dryness in vacuo and the residue stirred with dilute ammonia and extracted with chloroform. The chloroform extract was dried over sodium sulfate and solvent then removed in vacuo. The residue was crystallized from a mixture of benzene and hexane yielding 2-amino-4-methoxypheny1 2-thienyl ketone which upon recrystallization from hexane melted at 75-76".
Example 10 A solution of 1.5 g. of 2-amino-4-methoxyphenyl 2- thienyl ketone and 1.3 g. of glycine ethyl ester hydrochloride in 25 cc. of pyridine was refluxed for 1 hour. After distilling off 5 cc. of pyridine, an additional 1.3 g. of glycine ethyl ester hydrochloride was added and the reaction mixture stirred and refluxed for 16 hours. After concentration to dryness in vacuo, the residue was partitioned between benzene and water. The benzene layer was concentrated to dryness in vacuo and the residue was crystallized from benzene-hexane to give S-methoxy- 5-(2-thienyl)-3H-1,4-benzodiazepin 2(1H) one which after decolorization in acetone was recrystallized frombenzene-hexane and melted at 2125-214". Additional product was obtained by making the aqueous layer alkaline.
Example 11 Thiophene magnesium bromide prepared by the reaction of 17.8 g. of 2-bromo-thiophene with 2.6 g. of magnesium in 200 cc. of ether was slowly added to 16.1 g. of 2-methyl-3,1-4H-benzoxazine-4-one dissolved in 300 cc. of benzene and 100 cc. of ether while keeping the temperature at 5. A yellow precipitate formed. The reaction mixture was kept at 0-5 for hr. and then for 1 hr. at room temperature. It was then chilled in a salt-ice bath and decomposed by the addition of 200 cc. of cold 2 N hydrochloric acid. The organic layer was separated and the mother liquors concentrated to dryness leaving a residue which wa dissolved in 900 cc. of ether and 300 cc. of hexane and passed through a column containing 250 g. of Woelm alumina, neutral grade I. On elution with ether, and after crystallization from hexane Z-acetaminophenyl Z-thienyl ketone, was obtained which after recrystallization from hexane melted at 95-96.
Example 12 A solution of 11.0 g. of Z-acetaminophenyl 2-thienyl ketone in 200 cc. of ethanol and cc. of 6 N hydrochloric acid was refluxed for 2 /2 hrs. On cooling 8.0 g. of Z-aminophenyl 2-thienyl ketone hydrochloride crystallized. The free base was liberated (6.8 g.) but was not crystallized. An additional 2.2 g. of Z-aminophenyl Z-thienyl ketone was isolated from the alcoholic mother liquors. A solution of 9.0 g. of Z-aminophenyl 2-thienyl ketone and 9.3 g. of glycine ethyl ester hydrochloride in 100 cc. of pyridine was refluxed for 1 hr., then 15 cc. of pyridine was slowly distilled off. An additional 9.3 g. of glycine ethyl ester hydrochloride and 15 cc. of pyridine was added and refluxing continued for a total of 10 hrs. After concentration to dryness in vacuo, the residue was partitioned between benzene and water. The benzene layer was dried (sodium sulfate) and concentrated to dryness in vacuo. The residue upon crystallization from benzenehexane afforded 5-(2-thienyl)-3H-l,4-benzodiazepine-2- (1-H)-one which upon recrystallization from benzenehexane melted at l97l98. Additional product was obtained by neutralization of the aqueous layer obtained above. Also the organic mother liquors from the crystallization were taken to dryness and refluxed for 17 hours in 50 cc. of pyridine with 5.0 g. of glycine ethyl ester hydrochloride to yield still additional product.
Example 13 A solution of 3.0 g. of 2-aminophenyl 2-thienyl ketone in 150 cc. of ether was stirred with 50 cc. of 0.5 N sodium hydroxide at 5, and 3.1 g. of bromoacetyl bromide was then slowly added. After 30 minutes in the ice bath, the organic layer was separated, diluted with benzene, washed with water, and dried over sodium sulfate. After distillation of solvent in vacuo, the residue of crude 2-bromoacetamino 2-thienyl ketone was dissolved in 100 cc. of 20% ammonia in methanol (w./v.) and kept overnight at room temperature. Solvent was then evaporated in vacuo and the residue extracted with hot benzene. On addition of hexane to the benzene extract, 5-(2-thienyl) 3H 1, 4-benzodiazepin-2(lH)-one crystallized.
Example 14 5.5 g. of 5-(2-thienyl)-3H-1,(4-benzodiazepin-2(1H)- one was slowly added to 50 cc. of concentrated sulfuric acid cooled to 5-10. When all had dissolved, a solution of 1.45 cc. of nitric acid (d=1.42) in 5 cc. of concentrated sulfuric acid was added dropwise while keeping the temperature between and After all the acid was added, the reaction was kept at 0 for 1 hr. and then poured onto ice and made slightly alkaline with ammonia. The crude product was filtered off and recrystallized from acetonitrile. In this manner 7-nitro-5-(2- thienyl)-3H-1,4-benzodiazepin-2(1H)-one was obtained, which upon recrystallization from acetonitrile melted at 265466".
Example A Grignard reagent prepared by the reaction of 26.1 g. of 2-bromothiophene and 3.9 g. of magnesium in 200 cc. of ether was slowly added to a suspension of 29.3 g. of 6-chloro-2-methyl-3,1-4H-benzoxazin-4-one in 450 cc. of benzene and 150 cc. of ether while maintaining the temperature at 05. A yellow precipitate formed. The reaction mixture was stirred for 4 hr. in an ice bath and for hr. at room temperature, then chilled in a salt-ice bath, and decomposed by the addition of 250 cc. of cold 2 N hydrochloric acid. The organic layer was separated, washed with water, dilute sodium hydroxide, and water, then dried over sodium sulfate. A greenish yellow oil was obtained after evaporation of the solvent in vacuo. Crystallization from benzene-hexane gave crude product which after recrystallization from hexane, in which a portion was insoluble, yielded 2-acetamino- 5- chlorophenyl Z-thienyl ketone melting at 1l2ll5. Additional product could be recovered from the original benzene-hexane mother liquor.
8 Example 16 Crude Z-acetamino-S-chlorophenyl 2-thienyl ketone prepared as described above in Example 15 in a 0.05 mol run was hydrolyzed by refluxing for 2 hrs. with cc. of ethanol and 50 cc. of concentrated hydrochloric acid. After evaporation of the reaction mixture to dryness in vacuo the residue was stirred with water and the resulting yellow crystalline product filtered off. Crystallization from hexane yielded 2-amino-5-chlorophenyl 2- thienyl ketone which upon further crystallization from hexane melted at 94.5-96".
Example 17 20.8 g. of 2-acetamino-5-chlorophenyl 2-thienyl ketone was hydrolyzed by refluxing in 400 cc. of ethanol and 200 cc. of 6 N hydrochloric acid for 3 hrs. The solvent was distilled off in vacuo and the residue stirred with 200 cc. of ether and 200 cc. of water. The reaction mixture was made slightly alkaline with 40% sodium hydroxide, cooled to 05, and 15.0 g. of bromoacetyl bromide slowly added with the simultaneous addition of 1 N sodium hydroxide to keep the reaction alkaline. When the reaction was completed, benzene was added to dilute the organic layer and the solid that had separated in the aqueous layer was filtered off and dried. The product was 2-bromo-acetamino-S-chlorophenyl 2- thienyl ketone which upon being recrystallized twice from benzene-hexane melted at 148-149.5.
Example 18 A solution of 4 g. of 2-amino-5-chlorophenyl 2-thienyl ketone and 3.5 g. of glycine ethyl ester hydrochloride in 75 cc. of pyridine was heated to reflux for 1 hr. After distilling off 10 cc. of pyridine, an additional 3.5 g. of glycine ethyl ester hydrochloride was added and the reaction refiuxed for a total of 17 hrs. Solvent was evaporated in vacuo and the residue was partitioned between benzene and water. The organic layer was dried over sodium sulfate, concentrated to dryness in vacuo, and the residue crystallized from benzene-hexane to yield 7- chloro 5 (2 thienyl) 3H 1,4 benzodiazepin- 2(1H)-one which upon recrystallization from benzenehexane melted at 212-2135.
Example 19 14.9 g. of 2-bromoacetamino-5-chlorophenyl Z-thienyl ketone was stirred for 17 hrs. with 500cc. of 20% (w./v.) ammonia in methanol for 17 hrs. A small amount of insoluble material was filtered off and the filtrate concentrated to dryness in vacuo. The residue was partitioned between benzene and water and the organic layer separated, dried over sodium sulfate and concentrated to dryness in vacuo. The residual 5.2 g. which did not crystallize was redissolved in benzene and extracted with dilute hydrochloric acid. Only 600 mg. of yellow material remained in the benzene layer. The acid layer was made slightly alkaline with dilute sodium hydroxide and reextracted with benzene. The residue of 4.5 g., obtained by evaporation of solvent, was crystallized from acetonehexane to give 7-chloro-5- (2-thienyl)-3H-1,4-benzodiazepin-2( 1H) -one.
Example 20 benzene gave a product of constant melting point 142- 143.5
9 Example 21 1.2 cc. of chloroacetyl chloride was added to a solution of 1.95 g. of the 2-amino-5-chlorophenyl 2-thienyl ketoxime obtained above in Example 20 in 10 cc. of acetic acid. There was a slight heat of reaction and the mixture was then kept at Gil-70 for 2 hrs. Solvent was then distilled off in vacuo, and the residue dissolved twice in benzene and concentrated to dryness in vacuo. The residue thus obtained was slurried with ether and filtered yielding 6 chloro 2 chl-oromethyl 4 (2 thienyl)- quinazoline 3-oxide which upon crystallization from benzene-hexane melted at 159"-160.
Example 22 A suspension of 850 mg. of 6-chloro-2-chloromethyl-4- (2-thienyl)quinazoline 3-oxide in 20 cc. of 40% methylamine in methanol was stirred for 30 minutes in an ice bath and then stirred for 2 hrs. at room temperature. After chilling overnight in the refrigerator, 7-chloro-2- methylamino 5 (2 thienyl) 3H 1,4 benzodiazepine 4-oxide was filtered off and after crystallization from ethanol melted at 274-27 6.
Example 23 A suspension of 1.0 g. of 6-chloro-2-chloromethyl-4 (2-thienyl)quinazoline 3-oxide in a mixture of 25 cc. of ethanol, 3.2 cc, of 1 N sodium hydroxide, and 5 cc. of acetone was stirred at 35 for /2 hr. and then for 16 hrs. at room temperature, A crystalline product was filtered off and the ethanol filtrate concentrated to dryness in vacuo to yield a residue Which was crystallized from acetonitrile to yield 7-chloro-5-( 2-thienyl)-3H-1,4-benzodiazepin-2(1H)-one 4-oxide which upon crystillization from acetonitrile melted at 252-254 (dec.).
Example 24 To a solution of 1.12 g. of sodium methoxide in 100 cc. of methanol, 5.0 g. of 5-(2-thienyl)-3H-1,4-benzodiazepin-2-(1H)-one was added. After stirring for 30 minutes, the mixture was concentrated to dryness in vacuo. The residue was dissolved in 50 cc. of dimethylformamide and concentrated to a small volume in vacuo to remove traces of methanol. The residue was again diswherein R is selected from the group consisting of hydrogen, halogen, nitro and lower alkoxy; and R is selected from the group consisting of pyrryl and furyl.
2. A compound of the formula wherein R is selected from the group consisting of hydrogen, halogen, nitro and lower alkoxy, and R is selected from the group consisting of pyrryl and furyl.
3. 2-amin-o-5-halophenyl-R -ketoxime; wherein R is selected from the group consisting of pyrryl and furyl.
4. 6 halo 2 chloromethyl 4 R quinazoline 3-oxide; wherein R is selected from the group consisting of pyrryl and furyl.
References Cited UNITED STATES PATENTS 3,344,183 9/1967 Reeder et a1. 260--556 HENRY R. JILES, Primary Examiner.
ROBERT T. BOND, Assistant Examiner.
Claims (2)
1. A COMPOUND OF THE FORMULA
2. A COMPOUND OF THE FORMULA
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL131733D NL131733C (en) | 1961-06-20 | ||
NL279830D NL279830A (en) | 1961-06-20 | ||
NL122319D NL122319C (en) | 1961-06-20 | ||
US118243A US3405122A (en) | 1961-06-20 | 1961-06-20 | Novel 3h-1, 4-benzodiazepin-2-(1h)-ones |
US130757A US3100770A (en) | 1961-06-20 | 1961-08-11 | 5-pyridyl-1,4-benzodiazepine compounds |
CH712762A CH425808A (en) | 1961-06-20 | 1962-06-14 | Process for the preparation of benzodiazepine derivatives |
CH734566A CH445501A (en) | 1961-06-20 | 1962-06-14 | Process for the preparation of benzodiazepine derivatives |
CH1591566A CH450438A (en) | 1961-06-20 | 1962-06-14 | Process for the preparation of benzodiazepine derivatives |
CH734666A CH445502A (en) | 1961-06-20 | 1962-06-14 | Process for the preparation of benzodiazepine derivatives |
DE19621445862 DE1445862A1 (en) | 1961-06-20 | 1962-06-16 | Process for the preparation of benzodiazepine derivatives |
FR901235A FR1978M (en) | 1961-06-20 | 1962-06-19 | Medicinal product based on benzodiazepine derivatives. |
FR901140A FR1326838A (en) | 1961-06-20 | 1962-06-19 | Process for the preparation of benzodiazepine derivatives |
GB23491/62A GB948888A (en) | 1961-06-20 | 1962-06-19 | Novel benzodiazepine derivatives |
SE3477/64A SE303752B (en) | 1961-06-20 | 1962-06-20 | |
SE6895/62A SE301811B (en) | 1961-06-20 | 1962-06-20 | |
US326341A US3407211A (en) | 1961-06-20 | 1963-11-27 | Acylaminophenyl heterocyclic ketones |
US326340A US3398159A (en) | 1961-06-20 | 1963-11-27 | Aminophenyl heterocyclic ketones |
US326338A US3400128A (en) | 1961-06-20 | 1963-11-27 | Heterocyclic intermediates |
NL6700180A NL6700180A (en) | 1961-06-20 | 1967-01-05 | |
SE1640067A SE317682B (en) | 1961-06-20 | 1967-11-29 | |
SE5222/68A SE343060B (en) | 1961-06-20 | 1968-04-18 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US118243A US3405122A (en) | 1961-06-20 | 1961-06-20 | Novel 3h-1, 4-benzodiazepin-2-(1h)-ones |
US130757A US3100770A (en) | 1961-06-20 | 1961-08-11 | 5-pyridyl-1,4-benzodiazepine compounds |
US326340A US3398159A (en) | 1961-06-20 | 1963-11-27 | Aminophenyl heterocyclic ketones |
US326341A US3407211A (en) | 1961-06-20 | 1963-11-27 | Acylaminophenyl heterocyclic ketones |
US326338A US3400128A (en) | 1961-06-20 | 1963-11-27 | Heterocyclic intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
US3400128A true US3400128A (en) | 1968-09-03 |
Family
ID=27537521
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US118243A Expired - Lifetime US3405122A (en) | 1961-06-20 | 1961-06-20 | Novel 3h-1, 4-benzodiazepin-2-(1h)-ones |
US130757A Expired - Lifetime US3100770A (en) | 1961-06-20 | 1961-08-11 | 5-pyridyl-1,4-benzodiazepine compounds |
US326338A Expired - Lifetime US3400128A (en) | 1961-06-20 | 1963-11-27 | Heterocyclic intermediates |
US326341A Expired - Lifetime US3407211A (en) | 1961-06-20 | 1963-11-27 | Acylaminophenyl heterocyclic ketones |
US326340A Expired - Lifetime US3398159A (en) | 1961-06-20 | 1963-11-27 | Aminophenyl heterocyclic ketones |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US118243A Expired - Lifetime US3405122A (en) | 1961-06-20 | 1961-06-20 | Novel 3h-1, 4-benzodiazepin-2-(1h)-ones |
US130757A Expired - Lifetime US3100770A (en) | 1961-06-20 | 1961-08-11 | 5-pyridyl-1,4-benzodiazepine compounds |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US326341A Expired - Lifetime US3407211A (en) | 1961-06-20 | 1963-11-27 | Acylaminophenyl heterocyclic ketones |
US326340A Expired - Lifetime US3398159A (en) | 1961-06-20 | 1963-11-27 | Aminophenyl heterocyclic ketones |
Country Status (7)
Country | Link |
---|---|
US (5) | US3405122A (en) |
CH (4) | CH445501A (en) |
DE (1) | DE1445862A1 (en) |
FR (1) | FR1978M (en) |
GB (1) | GB948888A (en) |
NL (4) | NL6700180A (en) |
SE (4) | SE301811B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5036101A (en) * | 1989-10-30 | 1991-07-30 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with aryl-(2-pyrryl) ketone compound |
US5041438A (en) * | 1989-10-30 | 1991-08-20 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with benzodiazepine compounds |
US5141735A (en) * | 1990-06-18 | 1992-08-25 | Hoffman-La Roche, Inc. | Substituted amino-benzodiazepines having anitviral activity |
US5164376A (en) * | 1989-10-30 | 1992-11-17 | Hoffmann-Laroche Inc. | Method for treating retroviral infections with aryl-(2-pyrryl) keytone compound |
AU639273B2 (en) * | 1989-10-30 | 1993-07-22 | F. Hoffmann-La Roche Ag | Use of a benzodiazepine and a phenylpyrrylketone derivative |
WO1993017010A1 (en) * | 1992-02-26 | 1993-09-02 | F.Hoffmann-La Roche Ag | Benzodiazepinones and medicines containing them |
LT3028B (en) | 1992-06-16 | 1994-08-25 | Hoffmann La Roche | Benzodiazepine derivatives |
US5641773A (en) * | 1993-11-30 | 1997-06-24 | Dana-Farber Cancer Institute | Methods for treating viral infections |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3261828A (en) * | 1962-10-04 | 1966-07-19 | Hoffmann La Roche | 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds |
US3184448A (en) * | 1962-10-16 | 1965-05-18 | American Home Prod | Benzodiazepinium compounds |
US3336296A (en) * | 1962-10-26 | 1967-08-15 | American Home Prod | Preparation of 5-substituted-2h-1, 4-benzodiazepin-2-one-4-oxides |
US3192199A (en) * | 1963-03-01 | 1965-06-29 | Freeman H Mcmillan | Process for the production of 1-cycloalkyl derivatives of 1, 4-benzodiazepine |
US3321467A (en) * | 1963-11-27 | 1967-05-23 | Hoffmann La Roche | 3-halo-1, 4-benzodiazepin-2-ones |
US3182067A (en) * | 1964-04-09 | 1965-05-04 | Hoffmann La Roche | Benzodiazepine compounds |
NL131731C (en) * | 1965-12-09 | |||
US3678043A (en) * | 1966-03-14 | 1972-07-18 | American Home Prod | 2,3-dihydro-2-oxo-1h-1,4-benzodiazepine-3-carboxylic acid esters and related compounds |
US3429874A (en) * | 1966-12-22 | 1969-02-25 | Schering Corp | 1-polyhalogenoalkyl-2-oxo-1,3-dihydro-2h-1,4-benzodiazepines |
US3506403A (en) * | 1967-12-19 | 1970-04-14 | Hoffmann La Roche | Colorimetric method for determining iron in fluids |
US3506404A (en) * | 1967-12-19 | 1970-04-14 | Hoffmann La Roche | Colorimetric method for determining iron in blood |
US3551427A (en) * | 1969-05-09 | 1970-12-29 | Sandoz Ag | 4-thienyl-2-(1h)-quinazolones |
US3856802A (en) * | 1971-05-10 | 1974-12-24 | Upjohn Co | 1,6-DISUBSTITUTED-4H-5-{8 4,3-a{9 BENZODIAZEPINES |
US4089953A (en) * | 1973-06-20 | 1978-05-16 | Ddsa Pharmaceuticals | 1,5-Benzodiazocines |
DE3124013A1 (en) * | 1981-06-19 | 1982-12-30 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 2-ACYLAMINOMETHYL-1,4-BENZODIAZEPINE COMPOUNDS, METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
EP0491218A1 (en) * | 1990-12-17 | 1992-06-24 | F. Hoffmann-La Roche Ag | Benzodiazepinones |
AU2002317910B2 (en) * | 2001-06-07 | 2008-06-19 | Via Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
DE10161767A1 (en) * | 2001-12-15 | 2003-06-26 | Merck Patent Gmbh | New 2-guanidino-4-heterocyclyl-quinazoline derivatives, useful as sodium-proton antiporter subtype III inhibitors for treating e.g. respiratory, renal, ischemic or lipid metabolism disorders |
WO2012125787A1 (en) | 2011-03-17 | 2012-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFβ AND RUNX1 PROTEINS |
WO2018093797A1 (en) | 2016-11-15 | 2018-05-24 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
AU2018369784B2 (en) | 2017-11-14 | 2023-06-01 | Massachusetts Eye And Ear Infirmary | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
US11583497B2 (en) | 2017-11-14 | 2023-02-21 | The Schepens Eye Research Institute, Inc. | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery |
CN107903244B (en) * | 2017-11-29 | 2019-06-14 | 武汉珈创生物技术股份有限公司 | 2- amido with anti-tumor activity replaces Benzodiazepine compound and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3344183A (en) * | 1960-12-02 | 1967-09-26 | Hoffmann La Roche | 2 n-substituted amino benzophenones |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2928837A (en) * | 1960-03-15 | Chj-chj | ||
US2998421A (en) * | 1961-08-29 | Guanroevo compounds and method of | ||
US2997479A (en) * | 1955-07-01 | 1961-08-22 | Endo Lab | 1, 1-diphenyl-1-hydroxy-4-(pyrrolidyl)-butanone-2 |
US2962503A (en) * | 1956-11-21 | 1960-11-29 | American Cyanamid Co | Nitropyrroles |
US2944056A (en) * | 1957-05-22 | 1960-07-05 | Sumitomo Chemical Co | Method of producing quinazoline derivatives |
CH370076A (en) * | 1959-01-09 | 1963-06-30 | Cilag Chemie Aktiengesellschaf | Process for the production of new iodinated acid amides |
US2993905A (en) * | 1959-04-24 | 1961-07-25 | Us Vitamin Pharm Corp | Nu-dialkylaminoalkyl, nu-pyridylethyl anilines |
US2999091A (en) * | 1959-10-23 | 1961-09-05 | Abbott Lab | 3,9-diazabicyclo[4.2.1]nonane derivatives |
-
0
- NL NL279830D patent/NL279830A/xx unknown
- NL NL122319D patent/NL122319C/xx active
- NL NL131733D patent/NL131733C/xx active
-
1961
- 1961-06-20 US US118243A patent/US3405122A/en not_active Expired - Lifetime
- 1961-08-11 US US130757A patent/US3100770A/en not_active Expired - Lifetime
-
1962
- 1962-06-14 CH CH734566A patent/CH445501A/en unknown
- 1962-06-14 CH CH734666A patent/CH445502A/en unknown
- 1962-06-14 CH CH712762A patent/CH425808A/en unknown
- 1962-06-14 CH CH1591566A patent/CH450438A/en unknown
- 1962-06-16 DE DE19621445862 patent/DE1445862A1/en active Pending
- 1962-06-19 FR FR901235A patent/FR1978M/en active Active
- 1962-06-19 GB GB23491/62A patent/GB948888A/en not_active Expired
- 1962-06-20 SE SE6895/62A patent/SE301811B/xx unknown
- 1962-06-20 SE SE3477/64A patent/SE303752B/xx unknown
-
1963
- 1963-11-27 US US326338A patent/US3400128A/en not_active Expired - Lifetime
- 1963-11-27 US US326341A patent/US3407211A/en not_active Expired - Lifetime
- 1963-11-27 US US326340A patent/US3398159A/en not_active Expired - Lifetime
-
1967
- 1967-01-05 NL NL6700180A patent/NL6700180A/xx unknown
- 1967-11-29 SE SE1640067A patent/SE317682B/xx unknown
-
1968
- 1968-04-18 SE SE5222/68A patent/SE343060B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3344183A (en) * | 1960-12-02 | 1967-09-26 | Hoffmann La Roche | 2 n-substituted amino benzophenones |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5036101A (en) * | 1989-10-30 | 1991-07-30 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with aryl-(2-pyrryl) ketone compound |
US5041438A (en) * | 1989-10-30 | 1991-08-20 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with benzodiazepine compounds |
US5164376A (en) * | 1989-10-30 | 1992-11-17 | Hoffmann-Laroche Inc. | Method for treating retroviral infections with aryl-(2-pyrryl) keytone compound |
AU639273B2 (en) * | 1989-10-30 | 1993-07-22 | F. Hoffmann-La Roche Ag | Use of a benzodiazepine and a phenylpyrrylketone derivative |
US5141735A (en) * | 1990-06-18 | 1992-08-25 | Hoffman-La Roche, Inc. | Substituted amino-benzodiazepines having anitviral activity |
WO1993017010A1 (en) * | 1992-02-26 | 1993-09-02 | F.Hoffmann-La Roche Ag | Benzodiazepinones and medicines containing them |
LT3028B (en) | 1992-06-16 | 1994-08-25 | Hoffmann La Roche | Benzodiazepine derivatives |
US5641773A (en) * | 1993-11-30 | 1997-06-24 | Dana-Farber Cancer Institute | Methods for treating viral infections |
Also Published As
Publication number | Publication date |
---|---|
NL131733C (en) | |
US3407211A (en) | 1968-10-22 |
DE1445862A1 (en) | 1969-01-30 |
SE343060B (en) | 1972-02-28 |
NL279830A (en) | |
SE301811B (en) | 1968-06-24 |
CH425808A (en) | 1966-12-15 |
FR1978M (en) | 1963-08-19 |
CH445501A (en) | 1967-10-31 |
US3405122A (en) | 1968-10-08 |
SE317682B (en) | 1969-11-24 |
US3100770A (en) | 1963-08-13 |
US3398159A (en) | 1968-08-20 |
GB948888A (en) | 1964-02-05 |
SE303752B (en) | 1968-09-09 |
NL6700180A (en) | 1967-03-28 |
NL122319C (en) | |
CH450438A (en) | 1968-01-31 |
CH445502A (en) | 1967-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3400128A (en) | Heterocyclic intermediates | |
US3371085A (en) | 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones | |
Bell et al. | 3-Substituted 1, 4-benzodiazepin-2-ones | |
US3121075A (en) | Aminobenzodiazepines | |
US3341592A (en) | 2-amino-2'-trifluoromethyl-benzophenones | |
US4094984A (en) | 6-Phenyl-8-bromo-4H-s-triazolo-[3,4C]-thieno-[2,3E]-1,4-diazepines and salts thereof | |
US3131178A (en) | Process for producing s-phenyl-l | |
Koebel et al. | Synthesis of thieno [2, 3-b] azepin-4-ones as potential antineoplastic agents | |
US3202661A (en) | Substituted 3-amino 4-phenyl quinolones | |
US3402171A (en) | Process for preparing 5-aryl-3h-1, 4-benzodiazepin-2(1h)-ones | |
US3121114A (en) | Certificate of correction | |
US3182054A (en) | Benzodiazepine - compounds | |
US3121074A (en) | Nitro substituted jh-l | |
NO126799B (en) | ||
US3920687A (en) | 2,3,6,7-tetrahydro-6-phenyl-5h-imidazo(1,2-d)+8 1,4)benzodiazepin-5-ones and diazepines | |
US4102881A (en) | Benzodiazepine derivatives | |
US3239564A (en) | 2 n-substituted amino halobenzo-phenones | |
US4116956A (en) | Benzodiazepine derivatives | |
Derieg et al. | 1, 5-Benzodiazocines | |
DE1445863A1 (en) | Process for the preparation of benzodiazepine derivatives | |
US4009175A (en) | 1-[(Aminooxy)-methyl]-6-substituted-4H-s-triazolo[4,3-a][1,4] benzodiazepines | |
US3329701A (en) | Cyanobenzophenones | |
US3182065A (en) | 2-acetamidobenzoyl-pyridines | |
US3311612A (en) | Process for preparing | |
DK156391B (en) | ANALOGY PROCEDURE FOR PREPARING 3-AMINOPYR ROLLER DERIVATIVES |